Composition Wealth LLC Purchases 3,818 Shares of AbbVie Inc. $ABBV

Composition Wealth LLC grew its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 5.6% during the 3rd quarter, HoldingsChannel reports. The firm owned 71,696 shares of the company’s stock after buying an additional 3,818 shares during the period. Composition Wealth LLC’s holdings in AbbVie were worth $18,755,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of ABBV. Verus Financial Partners Inc. lifted its stake in shares of AbbVie by 1.7% in the third quarter. Verus Financial Partners Inc. now owns 2,048 shares of the company’s stock worth $536,000 after buying an additional 35 shares in the last quarter. Evergreen Private Wealth LLC boosted its position in AbbVie by 3.3% during the third quarter. Evergreen Private Wealth LLC now owns 1,090 shares of the company’s stock worth $285,000 after acquiring an additional 35 shares during the last quarter. Lifelong Wealth Advisors Inc. boosted its position in AbbVie by 2.1% during the third quarter. Lifelong Wealth Advisors Inc. now owns 1,755 shares of the company’s stock worth $459,000 after acquiring an additional 36 shares during the last quarter. IMG Wealth Management Inc. boosted its position in AbbVie by 22.8% during the third quarter. IMG Wealth Management Inc. now owns 194 shares of the company’s stock worth $51,000 after acquiring an additional 36 shares during the last quarter. Finally, Foundry Financial Group Inc. grew its stake in AbbVie by 4.6% during the 3rd quarter. Foundry Financial Group Inc. now owns 839 shares of the company’s stock valued at $219,000 after acquiring an additional 37 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Leerink Partners increased their price objective on shares of AbbVie from $309.00 to $342.00 and gave the company an “outperform” rating in a report on Monday, November 2nd. BNP Paribas Exane boosted their target price on AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a report on Tuesday, August 11th. Canaccord Genuity Group boosted their target price on AbbVie from $290.00 to $338.00 and gave the stock a “buy” rating in a report on Monday, November 2nd. Barclays upped their price target on AbbVie from $325.00 to $335.00 and gave the company an “overweight” rating in a research report on Monday. Finally, The Goldman Sachs Group upped their price target on AbbVie from $258.00 to $294.00 and gave the company a “neutral” rating in a research report on Friday, October 23rd. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and an average target price of $297.85.

Get Our Latest Stock Report on ABBV

AbbVie Stock Down 0.7%

NYSE ABBV opened at $292.40 on Wednesday. The business’s fifty day simple moving average is $277.14 and its 200-day simple moving average is $241.64. The firm has a market cap of $516.85 billion, a PE ratio of 50.33, a P/E/G ratio of 1.34 and a beta of 0.20. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $302.93.

AbbVie (NYSE:ABBV – Get Free Report) last announced its quarterly earnings data on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.73 by $0.09. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. The firm had revenue of $17.40 billion during the quarter, compared to analyst estimates of $17.32 billion. During the same quarter in the prior year, the firm posted $1.86 earnings per share. AbbVie’s quarterly revenue was up 10.3% on a year-over-year basis. Research analysts expect that AbbVie Inc. will post 13.98 EPS for the current year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 16th. Shareholders of record on Friday, January 15th will be issued a $1.82 dividend. This represents a $7.28 annualized dividend and a yield of 2.5%. The ex-dividend date is Friday, January 15th. This is a positive change from AbbVie’s previous quarterly dividend of $1.73. AbbVie’s dividend payout ratio (DPR) is presently 119.10%.

Top AbbVie Stories

Investors following ABBV have been watching these stories:

Insiders Place Their Bets

In other AbbVie news, EVP Jeffrey Stewart sold 40,619 shares of the business’s stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $293.60, for a total value of $11,925,738.40. Following the transaction, the executive vice president directly owned 83,171 shares in the company, valued at $24,419,005.60. The trade was a 32.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.06% of the stock is owned by insiders.

AbbVie Profile

(Free Report)

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.

Featured Articles

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.